Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 12/2016

01-08-2016 | Review Article

Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients

Authors: Antonio D’Avolio, Debora Pensi, Lorena Baietto, Giovanni Pacini, Giovanni Di Perri, Francesco Giuseppe De Rosa

Published in: Drugs | Issue 12/2016

Login to get access

Abstract

Infections, including sepsis, are associated with high mortality rates in critically ill patients in the intensive care unit (ICU). Appropriate antibiotic selection and adequate dosing are important for improving patient outcomes. Daptomycin is bactericidal in bloodstream infections caused by Staphylococcus aureus and other Gram-positive pathogens cultured in ICU patients. The drug has concentration-dependent activity, and the area under the curve/minimum inhibitory concentration ratio is the pharmacokinetic/pharmacodynamic (PK/PD) index that best correlates with daptomycin activity, whereas toxicity correlates well with daptomycin plasma trough concentrations (or minimum concentration [C min]). Adequate daptomycin exposure can be difficult to achieve in ICU patients; multiple PK alterations can result in highly variable plasma concentrations, which are difficult to predict. For this reason, therapeutic drug monitoring could help clinicians optimize daptomycin dosing, thus improving efficacy while decreasing the likelihood of serious adverse events. This paper reviews the literature on daptomycin in ICU patients with sepsis, focusing on dosing and PK and PD parameters.
Literature
1.
Lai CC, Sheng WH, Wang JT, Cheng A, Chuang YC, Chen YC, et al. Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. BMC Infect Dis. 2013;13:66.PubMedPubMedCentralCrossRef
2.
Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.PubMedCrossRef
3.
Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–65.PubMedCrossRef
4.
5.
Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs. 2004;64(15):1621–42.PubMedCrossRef
6.
Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy. 2009;29(7):792–9.PubMedCrossRef
7.
8.
Munita JM, Murray BE, Arias CA. Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci. Int J Antimicrob Agents. 2014;44(5):387–95.PubMedPubMedCentralCrossRef
9.
Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2001;45(3):845–51.PubMedPubMedCentralCrossRef
10.
11.
Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000;44(11):2948–53.PubMedPubMedCentralCrossRef
12.
Tally FP, Zeckel M, Wasilewski MM, Carini C, Berman CL, Drusano GL, et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs. 1999;8(8):1223–38.PubMedCrossRef
13.
Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50(12):1568–74.PubMedCrossRef
14.
Bonora S, Lanzafame M, D’Avolio A, Trentini L, Lattuada E, Concia E, et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis. 2008;46(1):146–7.PubMedCrossRef
15.
Gonzalez de Requena D, Calcagno A, Bonora S, Ladetto L, D’Avolio A, Sciandra M, et al. Unexpected drug–drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS. 2006;20(15):1977–9.PubMedCrossRef
16.
Hites M, Dell’Anna AM, Scolletta S, Taccone FS. The challenges of multiple organ dysfunction syndrome and extra-corporeal circuits for drug delivery in critically ill patients. Adv Drug Deliv Rev. 2014;77:12–21.PubMedCrossRef
17.
Nicolau DP. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother. 2003;9(4):292–6.PubMedCrossRef
18.
Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840–51 (quiz 59).PubMedCrossRef
19.
Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50(10):3245–9.PubMedPubMedCentralCrossRef
20.
Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47(4):1318–23.PubMedPubMedCentralCrossRef
21.
Rybak MJ. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin Microbiol Infect. 2006;12(Suppl 1):24–32.PubMedCrossRef
22.
Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 1992;36(2):318–25.PubMedPubMedCentralCrossRef
23.
Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother. 2002;46(1):31–3.PubMedPubMedCentralCrossRef
24.
Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48(8):2799–807.PubMedPubMedCentralCrossRef
25.
Reiber C, Senn O, Muller D, Kullak-Ublick GA, Corti N. Therapeutic drug monitoring of daptomycin: a retrospective monocentric analysis. Ther Drug Monit. 2015;37(5):634–40.PubMedCrossRef
26.
Di Paolo A, Tascini C, Polillo M, Gemignani G, Nielsen EI, Bocci G, et al. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. Int J Antimicrob Agents. 2013;42(3):250–5.PubMedCrossRef
27.
Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, d’Ettorre G, et al. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J Infect Chemother. 2013;19(4):732–9.PubMedCrossRef
28.
Pea F, Cojutti P, Sbrojavacca R, Cadeo B, Cristini F, Bulfoni A, et al. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother. 2011;45(7–8):e37.PubMedCrossRef
29.
Pea F, Crapis M, Cojutti P, Bassetti M. Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. Infection. 2013;42(1):207–10.PubMedCrossRef
30.
Baietto L, Corcione S, Pacini G, Di Perri G, D’Avolio A, De Rosa FG. A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? Curr Drug Metab. 2014;15(6):581–98.PubMedPubMedCentralCrossRef
31.
Schipani A, Siccardi M, D’Avolio A, Baietto L, Simiele M, Bonora S, et al. Population pharmacokinetic modeling of the association between 63396C→T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother. 2010;54(12):5242–50.PubMedPubMedCentralCrossRef
32.
D’Avolio A, Cusato J, Calcagno A, Di Perri G. Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring? J Hepatol. 2013;59(3):633–4.PubMedCrossRef
33.
Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells. Antimicrob Agents Chemother. 2007;51(8):2748–57.PubMedPubMedCentralCrossRef
34.
Baietto L, D’Avolio A, Cusato J, Pace S, Calcagno A, Motta I, et al. Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. J Antimicrob Chemother. 2015;70(1):307–8.PubMedCrossRef
35.
Baietto L, D’Avolio A, De Rosa FG, Garazzino S, Michelazzo M, Ventimiglia G, et al. Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. Anal Bioanal Chem. 2010;396(2):791–8.PubMedCrossRef
36.
Baietto L, D’Avolio A, Pace S, Simiele M, Marra C, Ariaudo A, et al. Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. J Pharm Biomed Anal. 2014;88:66–70.PubMedCrossRef
37.
Polillo M, Tascini C, Lastella M, Malacarne P, Ciofi L, Viaggi B, et al. A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther Drug Monit. 2010;32(2):200–5.PubMed
38.
Pai MP, Russo A, Novelli A, Venditti M, Falcone M. Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example. Antimicrob Agents Chemother. 2014;58(6):3162–7.PubMedPubMedCentralCrossRef
39.
D’Avolio A, Pensi D, Baietto L, Di Perri G. Therapeutic drug monitoring of intracellular anti-infective agents. J Pharm Biomed Anal. 2014;101:183–93.PubMedCrossRef
40.
Kanzler I, Weis F, Beiras-Fernandez A. Current use of daptomycin in cardiac surgery and postoperative intensive care. Expert Rev Anti Infect Ther. 2013;11(3):309–20.PubMedCrossRef
41.
Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther. 2009;31(9):1936–45.PubMedCrossRef
42.
European Medicines Agency. Cubicin (daptomycin). EMEA/H/C/000637. London: European Medicines Agency; 2006.
43.
Vilhena C, Bettencourt A. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Rev Med Chem. 2012;12(3):202–9.PubMedCrossRef
44.
45.
Debono M, Abbott BJ, Molloy RM, Fukuda DS, Hunt AH, Daupert VM, et al. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J Antibiot (Tokyo). 1988;41(8):1093–105.PubMedCrossRef
46.
Yazawa M, Yagi K. The amino acid sequence of the calmodulin obtained from sea anemone (metridium senile) muscle. Biochem Biophys Res Commun. 1980;96(1):377–81.PubMedCrossRef
47.
48.
Eckmann C, Dryden M, Montravers P, Kozlov R, Sganga G. Antimicrobial treatment of “complicated” intra-abdominal infections and the new IDSA guidelines? A commentary and an alternative European approach according to clinical definitions. Eur J Med Res. 2011;16(3):115–26.PubMedPubMedCentralCrossRef
49.
European Medicines Agency. Cubicin: EPAR—scientific discussion (WC500036046.pdf). European Medicines Agency; 2006.
50.
European Medicines Agency. Cubicin: EPAR—product information (WC500036049.pdf). European Medicines Agency; 2006.
51.
Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47(8):2538–44.PubMedPubMedCentralCrossRef
52.
Baltz RH, Miao V, Wrigley SK. Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat Prod Rep. 2005;22(6):717–41.PubMedCrossRef
53.
Ho SW, Jung D, Calhoun JR, Lear JD, Okon M, Scott WR, et al. Effect of divalent cations on the structure of the antibiotic daptomycin. Eur Biophys J. 2008;37(4):421–33.PubMedCrossRef
54.
Jung D, Rozek A, Okon M, Hancock RE. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004;11(7):949–57.PubMedCrossRef
55.
Muraih JK, Pearson A, Silverman J, Palmer M. Oligomerization of daptomycin on membranes. Biochim Biophys Acta. 2011;1808(4):1154–60.PubMedCrossRef
56.
Straus SK, Hancock RE. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta. 2006;1758(9):1215–23.PubMedCrossRef
57.
Bayer AS, Schneider T, Sahl HG. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci. 2013;1277:139–58.PubMedCrossRef
58.
Gasch O, Camoez M, Dominguez MA, Padilla B, Pintado V, Almirante B, et al. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. J Antimicrob Chemother. 2014;69(2):568–71.PubMedCrossRef
59.
Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis. 2009;9(10):617–24.PubMedCrossRef
60.
Sharma M, Riederer K, Chase P, Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2008;27(6):433–7.PubMedCrossRef
61.
Yang SJ, Mishra NN, Rubio A, Bayer AS. Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob Agents Chemother. 2013;57(11):5658–64.PubMedPubMedCentralCrossRef
62.
Song Y, Rubio A, Jayaswal RK, Silverman JA, Wilkinson BJ. Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies. PLoS One. 2013;8(3):e58469.PubMedPubMedCentralCrossRef
63.
Mishra NN, Bayer AS, Weidenmaier C, Grau T, Wanner S, Stefani S, et al. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS One. 2014;9(9):e107426.PubMedPubMedCentralCrossRef
64.
Mishra NN, McKinnell J, Yeaman MR, Rubio A, Nast CC, Chen L, et al. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55(9):4012–8.PubMedPubMedCentralCrossRef
65.
Mishra NN, Yang SJ, Chen L, Muller C, Saleh-Mghir A, Kuhn S, et al. Emergence of daptomycin resistance in daptomycin-naive rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PLoS One. 2013;8(8):e71151.PubMedPubMedCentralCrossRef
66.
Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, et al. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(6):2312–8.PubMedPubMedCentralCrossRef
67.
Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care. 2011;15(5):R206.PubMedPubMedCentralCrossRef
68.
Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother. 1997;41(4):733–8.PubMedPubMedCentral
69.
Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents. 2007;30(3):202–9.PubMedCrossRef
70.
Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother. 2007;60(1):7–19.PubMedCrossRef
71.
Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2012;54(1):51–8.PubMedCrossRef
72.
Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann Pharmacother. 2009;43(7):1211–9.PubMedCrossRef
73.
Ballester F, Pujol I, Cueto P, Rovira C, Iftimie S, Camps J. Emergence of daptomycin-resistant Enterococcus faecium in a critically ill patient with postoperative intra-abdominal sepsis. Rev Esp Quimioter. 2015;28(2):109–10.PubMed
74.
Lewis JS 2nd, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49(4):1664–5.PubMedPubMedCentralCrossRef
75.
Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 2007;45(5):601–8.PubMedCrossRef
76.
Steed M, Vidaillac C, Rybak MJ. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2011;55(7):3522–6.PubMedPubMedCentralCrossRef
77.
Steed ME, Vidaillac C, Rose WE, Winterfield P, Kaatz GW, Rybak MJ. Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2011;55(10):4748–54.PubMedPubMedCentralCrossRef
78.
Steed ME, Vidaillac C, Rybak MJ. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2012;56(2):955–9.PubMedPubMedCentralCrossRef
79.
Vilay AM, Grio M, Depestel DD, Sowinski KM, Gao L, Heung M, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med. 2011;39(1):19–25.PubMedCrossRef
80.
Kullar R, Chin JN, Edwards DJ, Parker D, Coplin WM, Rybak MJ. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother. 2011;55(7):3505–9.PubMedPubMedCentralCrossRef
81.
Levine DP. Clinical experience with daptomycin: bacteraemia and endocarditis. J Antimicrob Chemother. 2008;62(Suppl 3):iii35–9.PubMed
82.
Abdel-Rahman SM, Chandorkar G, Akins RL, Bradley JS, Jacobs RF, Donovan J, et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J. 2011;30(8):712–4.PubMedCrossRef
83.
Kielstein JT, Eugbers C, Bode-Boeger SM, Martens-Lobenhoffer J, Haller H, Joukhadar C, et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis: a pharmacokinetic study. Nephrol Dial Transplant. 2010;25(5):1537–41.PubMedCrossRef
84.
Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813–8.PubMedCrossRef
85.
Burkhardt O, Joukhadar C, Traunmuller F, Hadem J, Welte T, Kielstein JT. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother. 2008;61(1):224–5.PubMedCrossRef
86.
Faulhaber-Walter R, Hafer C, Jahr N, Vahlbruch J, Hoy L, Haller H, et al. The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant. 2009;24(7):2179–86.PubMedCrossRef
87.
Fliser D, Kielstein JT. Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol. 2006;2(1):32–9.PubMedCrossRef
88.
Kumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis. 2000;36(2):294–300.PubMedCrossRef
89.
Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int. 2001;60(2):777–85.PubMedCrossRef
90.
Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs. 2003;27(9):808–14.PubMedCrossRef
91.
Preiswerk B, Rudiger A, Fehr J, Corti N. Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy. Infection. 2012;41(2):553–7.PubMedCrossRef
92.
Corti N, Rudiger A, Chiesa A, Marti I, Jetter A, Rentsch K, et al. Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy. Chemotherapy. 2013;59(2):143–51.PubMedCrossRef
93.
Wenisch JM, Meyer B, Fuhrmann V, Saria K, Zuba C, Dittrich P, et al. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2012;67(4):977–83.PubMedCrossRef
94.
Soon RL, Turner SJ, Forrest A, Tsuji BT, Brown J. Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus. Int J Antimicrob Agents. 2013;42(1):53–8.PubMedCrossRef
95.
Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49(2):177–80.PubMedCrossRef
96.
Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract. 2008;62(9):1455–64.PubMedCrossRef
97.
Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013;68(12):2921–6.PubMedPubMedCentralCrossRef
98.
Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011;31(6):527–36.PubMedCrossRef
99.
Kullar R, Sakoulas G, Deresinski S, van Hal SJ. When sepsis persists: a review of MRSA bacteraemia salvage therapy. J Antimicrob Chemother. 2016;71(3):576–86.PubMedCrossRef
100.
Bassetti M, Nicco E, Ginocchio F, Ansaldi F, de Florentiis D, Viscoli C. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents. 2010;36(5):459–61.PubMedCrossRef
101.
Falcone M, Russo A, Venditti M, Novelli A, Pai MP. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57(11):1568–76.PubMedCrossRef
102.
Di Paolo A, Polillo M, Tascini C, Lewis R, Menichetti F, Danesi R. Different recommendations for daptomycin dosing over time in patients with severe infections. Clin Infect Dis. 2014;58(12):1788–9.PubMedCrossRef
103.
Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55(5):601–7.PubMedCrossRef
104.
Wu G, Abraham T, Rapp J, Vastey F, Saad N, Balmir E. Daptomycin: evaluation of a high-dose treatment strategy. Int J Antimicrob Agents. 2011;38(3):192–6.PubMedCrossRef
105.
Nguyen MH, Eells SJ, Tan J, Sheth CT, Omari B, Flores M, et al. Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery. Antimicrob Agents Chemother. 2011;55(6):2499–505.PubMedPubMedCentralCrossRef
106.
Salem AH, Zhanel GG, Ibrahim SA, Noreddin AM. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus. Clin Exp Pharmacol Physiol. 2014;41(6):437–43.PubMedCrossRef
107.
Butterfield JM, Mueller BA, Patel N, Cardone KE, Grabe DW, Salama NN, et al. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. Antimicrob Agents Chemother. 2013;57(2):864–72.PubMedPubMedCentralCrossRef
108.
Cardone KE, Lodise TP, Patel N, Hoy CD, Meola S, Manley HJ, et al. Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol. 2011;6(5):1081–8.PubMedPubMedCentralCrossRef
109.
Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am. 2009;23(4):791–815, vii.
110.
Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009;53(2):428–34.PubMedCrossRef
111.
Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, Fallani S, et al. Daptomycin serum levels in critical patients undergoing continuous renal replacement. J Chemother. 2012;24(5):253–6.PubMedCrossRef
112.
Newham DJ, Jones DA, Edwards RH. Large delayed plasma creatine kinase changes after stepping exercise. Muscle Nerve. 1983;6(5):380–5.PubMedCrossRef
113.
Noakes TD, Kotzenberg G, McArthur PS, Dykman J. Elevated serum creatine kinase MB and creatine kinase BB-isoenzyme fractions after ultra-marathon running. Eur J Appl Physiol Occup Physiol. 1983;52(1):75–9.PubMedCrossRef
Metadata
Title
Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients
Authors
Antonio D’Avolio
Debora Pensi
Lorena Baietto
Giovanni Pacini
Giovanni Di Perri
Francesco Giuseppe De Rosa
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Drugs / Issue 12/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0610-3

Other articles of this Issue 12/2016

Drugs 12/2016 Go to the issue

AdisInsight Report

Obeticholic Acid: First Global Approval

Adis Drug Evaluation

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis

Adis Drug Evaluation

Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection

Adis Drug Evaluation

Diclofenac Sodium Bolus Injection (DylojectTM): A Review in Acute Pain Management

Review Article

Unmet Needs in LDL-C Lowering: When Statins Won’t Do!

Erratum

Erratum to: Olmutinib: First Global Approval